​Lomiko (LMRMF) to Discuss the Flake Graphite Market and the la Loutre Project at Booth 3209 March 4-7, 2018 Pdac 2018 in Toronto

Spotlight Companies  |

LOMIKO METALS INC. (TSXV:LMR,) (OTC: LMRMF) (FSE: DH8B) (ISIN: CA54163Q1028) (WKN: A0Q9W7) will exhibit at the Prospectors and Developers Association of Canada International Convention Trade Show and Investors Exchange March 4-7, 2018 at the Metro Toronto Convention Centre at Booth #3209. Lomiko Management look forward to meeting shareholders, potential investors and international delegations during their first attendance to the Convention.

Investment Pitch Media recently recorded a news update on Lomiko at the PDAC.

Graphite Market Developments
Roskill Information Services recently reported that Indian manufacturers of graphite electrodes used in electric arc furnaces are flourishing this year, but 500% price increases for their products have raised government and steel industry concerns.
Roskill view: India’s two synthetic graphite electrode manufacturers account for about 25% of world production of synthetic graphite electrodes and this intervention could cut margins and pile even more pressure on prices for India’s international customers such as ArcelorMittal and South Korea’s POSCO.
Graphite electrodes are used to melt scrap in electric arc furnaces to produce new steel. Their main ingredient is high-value petroleum needle coke.
China’s 13th Five-Year Plan (2016–2020) sets clear objectives for a more environmentally-friendly China. President Xi Jinping is focussed on pollution control as well as economic growth for his second term, with implications for the global supply chain in graphite electrodes as well as many other industrial raw materials. Approximately 30% of China’s graphite electrode production has been shut, leading to an explosion in global prices and benefiting manufacturers in other countries, including India.

In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Symbol Name Price Change % Volume
LMR:CA Lomiko Metals Inc. 0.05 0.01 25.00 628,060
LMRMF Lomiko Metals Inc Ord 0.04 0.01 28.42 299,000



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Ben Yablon Executive VP Salt Lending

Matt Bird sits down with Ben Yablon - Executive VP of Salt Lending - at the World Economic Forum in Davos January 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.